Abstract: The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the preparation of substantially pure tafluprost.

Abstract: Aspects of the present invention relate to amorphous form of mirabegron, amorphous solid dispersion of mirabegron, process for its preparation, processes for preparation of a form crystal and ? form crystal of mirabegron and pharmaceutical composition thereof.

Abstract: Aspects of the present application relate to a microcrystalline monoclinic form of asenapine maleate represented by structural Formula (I); processes for its preparation; and pharmaceutically acceptable dosage forms thereof.

Abstract: The invention provides an efficient method of purification of a modified cytokine. The process includes the use of a chromatographic technique for the purification of the desired cytokine. The purified cytokine can be used as a therapeutic composition.

Abstract: Provided is a method for purification of TNFR:Fc fusion protein comprising hydrophobic interaction chromatography, wherein the buffer solution used in the said chromatography does not contain any additives.

Abstract: There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.

Abstract: The invention provides a method of purification of antibodies using chromatographic technique. The method involves the use of cation-exchange chromatography for the purification of the antibody. The purified antibody can be used as a therapeutic composition.

Abstract: The present application relates to compositions for parenteral administration of epothilone compounds, such as ixabepilone.

Abstract: The present application relates to a process for purification of palonosetron or its salt substantially free of its R-isomer and structure related impurities.

Abstract: Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent.

Abstract: Stable premixes comprising retigabine, or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier, and process for preparing the same are disclosed. Stable premixes comprising retigabine, or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable inorganic carrier, and processes for preparing the same and incorporating them in compositions that are employed for therapeutic uses and methods of treatment.

Abstract: There is provided polymorphs and amorphous form of pemetrexed or its pharmaceutical acceptable salts and process for making thereof.

Abstract: The present disclosure provides pharmaceutical compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the compositions devoid of buffer and in the presence of alkaline oxides capable of raising the pH of saliva to a pH greater than about 7.0 thereby facilitate the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.

Abstract: Methods for reducing bone loss in a subject suffering from a condition benefiting from a decrease in insulin resistance, by balaglitazone administration to the subject.

Abstract: The present invention relates to novel crystalline Form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt having the formula (I). The invention also relates to a pharmaceutical composition comprising the novel crystalline Form and a pharmaceutically acceptable carrier. The novel crystalline Form of the present invention is more active, as an antidiabetic agent than the hitherto known 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt.

Abstract: There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical composition comprising the same.

Abstract: A process for preparing (4S,5R)-5-carboxymethyl-2,2-dimethyl-4-phenyl-oxazolidine-3-carboxylic acid t-butyl ester, an intermediate in the preparation of anticancer compounds having a taxane skeleton, such as paclitaxel, docetaxol, etc.

Abstract: There is provided an improved process for the preparation of Sitagliptin of Formula II by reduction of compound of Formula VIII to Formula IX followed by deprotection of Formula IX to afford Sitagliptin of Formula II.

Abstract: The present invention relates to taste masked pharmaceutical formulations, processes for preparing the same and methods of using them. The present invention relates to taste masked effervescent formulations comprising fexofenadine or a pharmaceutically acceptable salt thereof, processes for preparing the same, and therapeutic uses and methods of treatment employing such formulations.

Abstract: Pharmaceutical compositions comprising palonosetron and its pharmaceutically acceptable salts, in the form of a ready-to-use solution or a lyophilized form. Specific embodiments of the invention relate to stable pharmaceutical formulations of palonosetron and its pharmaceutically acceptable salts, wherein the formulation does not comprise a chelating agent or an antioxidant.